Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2532-2546

  Hanson, Melissa C ^a,b   Crespo, Monica P ^b   Abraham, Wuhbet ^b   Moynihan, Kelly D ^a,b   Szeto, Gregory L ^a,b,c   Chen, Stephanie H ^c   Melo, Mariane B ^b   Mueller, Stefanie ^b   Irvine, Darrell J ^a,b,c,d  

^a Department of Biological Engineering ^*  (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYCLIC DIGUANOSINE PHOSPHATE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; GLYCOPROTEIN GP 41; IMMUNOMODULATING AGENT; NANOCARRIER; NANOPARTICLE; PEPTIDE VACCINE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; BIS(3',5')-CYCLIC DIGUANYLIC ACID; CYCLIC GMP; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPID A; MACROGOL DERIVATIVE; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENCAPSULATION; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; LYMPH NODE; LYMPH VESSEL; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CYCLIC GMP; DRUG DELIVERY SYSTEMS; HIV ENVELOPE PROTEIN GP41; HIV-1; LIPID A; LYMPH NODES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYETHYLENE GLYCOLS;

EID: 84930388443     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79915     Document Type: Article

References (94)

1. Koff WC, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013;340(6136): 1232910.
2. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol. 2011;11(12): 865-872.
3. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: Putting innate immunity to work. Immunity. 2010;33(4): 492-503.
4. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12): 1597-1608.
5. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- And QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10(4): 471-486.
6. Dubensky TW, Kanne DB, Leong ML. Rationale, progress and development of vaccines utilizing STING-Activating cyclic dinucleotide adjuvants. Ther Adv. 2013;1(4): 131-143.
7. Römling U, Galperin MY, Gomelsky M. Cyclic di-GMP: The first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev. 2013;77(1): 1-52.
8. Ablasser A, et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498(7454): 380-384.
9. Wu J, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339(6121): 826-830.
10. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMPAMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121): 786-791.
11. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213): 674-678.
12. Woodward JJ, Iavarone AT, Portnoy DA. c-di- AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science. 2010;328(5986): 1703-1705.
13. Burdette DL, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478(7370): 515-518.
14. Karaolis DK, et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol. 2007;178(4): 2171-2181.
15. Ebensen T, Schulze K, Riese P, Morr M, Guzmán CA. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol. 2007;14(8): 952-958.
16. Yan H, et al. 3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem Biophys Res Commun. 2009;387(3): 581-584.
17. Libanova R, et al. The member of the cyclic dinucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine. 2010;28(10): 2249-2258.
18. Ebensen T, Schulze K, Riese P, Link C, Morr M, Guzmán CA. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine. 2007;25(8): 1464-1469.
19. Madhun AS, et al. Intranasal c-di-GMPadjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine. 2011;29(31): 4973-4982.
20. Bosch V, et al. HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats. Vaccine. 2009;27(16): 2202-2212.
21. Hu DL, Narita K, Hyodo M, Hayakawa Y, Nakane A, Karaolis DK. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin- resistant Staphylococcus aureus (MRSA) infection. Vaccine. 2009;27(35): 4867-4873.
22. Gray PM, et al. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol. 2012;278(1-2): 113-119.
23. Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol. 2007;47(8): 962-969.
24. Chen W, Kuolee R, Yan H. The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine. 2010;28(18): 3080-3085.
25. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater. 2013;12(11): 978-990.
26. Storni T, Kündig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev. 2005;57(3): 333-355.
27. Jewell CM, López SCB, Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A. 2011;108(38): 15745-15750.
28. Demento SL, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012;33(19): 4957-4964.
29. Bershteyn A, et al. Robust IgG responses to nanograms of antigen using a biomimetic lipidcoated particle vaccine. J Control Release. 2012;157(3): 354-365.
30. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A. 2012;109(4): 1080-1085.
31. Diwan M, Elamanchili P, Cao M, Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv. 2004;1(4): 405-412.
32. Kasturi SP, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470(7335): 543-547.
33. Pihlgren M, et al. TLR4- And TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood. 2013;121(1): 85-94.
34. Xie H, et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun. 2005;73(2): 828-833.
35. Coler RN, et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One. 2010;5(10): E13677.
36. Ilyinskii PO, et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine. 2014;32(24): 2882-2895.
37. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11(7): E1001685.
38. Behzad H, et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis. 2012;205(3): 466-473.
39. Rose S, Misharin A, Perlman H. A novel Ly6C/ Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytom A. 2012;81(4): 343-350.
40. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta. 1990;1029(1): 91-97.
41. Oussoren C, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm Res. 1997;14(10): 1479-1484.
42. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63(10-11): 901-908.
43. Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H. A new adjuvant delivery system "cyclic di-GMP/YSK05 liposome" for cancer immunotherapy. J Control Release. 2014;184: 20-27.
44. Chandra D, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res. 2014;2(9): 901-910.
45. Le Bon A, et al. Cutting edge: Enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006;176(4): 2074-2078.
46. Liu H, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493): 519-522.
47. Gach JS, Leaman DP, Zwick MB. Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr Top Med Chem. 2011;11(24): 2997-3021.
48. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008;72(1): 54-84.
49. Dai G, Steede NK, Landry SJ. Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120. J Biol Chem. 2001;276(45): 41913-41920.
50. Kim M, et al. Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. J Biol Chem. 2013;288(44): 31888-31901.
51. Abdul-Sater AA, et al. The overlapping host responses to bacterial cyclic dinucleotides. Microbes Infect. 2012;14(2): 188-197.
52. McWhirter SM, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med. 2009;206(9): 1899-1911.
53. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29: 621-663.
54. Sauer JD, et al. The N-ethyl-N-nitrosoureainduced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun. 2011;79(2): 688-694.
55. Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine. 2008;26(24): 3036-45.
56. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll- And nod-like receptors induces effective tumorspecific immune responses. Sci Transl Med. 2012;4(120): 120ra16.
57. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6(8): 769-776.
58. Cella M, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8): 919-923.
59. Siegal FP, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421): 1835-1837.
60. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med. 2011;208(12): 2367-2374.
61. Blaauboer SM, Gabrielle VD, Jin L. MPYS/ STING-mediated TNF-A, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo. J Immunol. 2014;192(1): 492-502.
62. Simon A, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-Associated periodic fever syndrome. Proc Natl Acad Sci U S A. 2010;107(21): 9801-9806.
63. Libanova R, Becker PD, Guzmán CA. Cyclic di-nucleotides: New era for small molecules as adjuvants. Microb Biotechnol. 2012;5(2): 168-176.
64. Ouyang S, et al. Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. Immunity. 2012;36(6): 1073-1086.
65. Shu C, Yi G, Watts T, Kao CC, Li P. Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol. 2012;19(7): 722-724.
66. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science. 2013;341(6152): 1390-1394.
67. Ogunniyi AD, et al. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine. 2008;26(36): 4676-4685.
68. Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzmán CA. Bis-(3',5')-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/ Th17 promoting mucosal adjuvant. Vaccine. 2011;29(32): 5210-5220.
69. McLennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005;2(1): 89-96.
70. Walder P, et al. Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. Immunopharmacol Immunotoxicol. 1991;13(1-2): 101-119.
71. Kulkarni RR, et al. Activation of RIG-I pathway during influenza vaccination enhances germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. J Virol. 2014;88(24): 13990-14001.
72. Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD. Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine. 2011;29(33): 5434-5442.
73. Krupka M, et al. Enhancement of immune response towards non-lipidized Borrelia burgdorferi recombinant OspC antigen by binding onto the surface of metallochelating nanoliposomes with entrapped lipophilic derivatives of norAbuMDP. J Control Release. 2012;160(2): 374-381.
74. Wu CC, et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A. 2007;104(10): 3990-3995.
75. Wille-Reece U, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A. 2005;102(42): 15190-15194.
76. Barker JR, et al. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. MBio. 2013;4(3): 1-11.
77. Spörri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol. 2005;6(2): 163-170.
78. Desch AN, et al. Dendritic cell subsets require cis-Activation for cytotoxic CD8 T-cell induction. Nat Commun. 2014;5: 4674.
79. Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson- Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity. 2009;31(3): 491-501.
80. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4): 461-470.
81. Parent MA, Wilhelm LB, Kummer LW, Szaba FM, Mullarky IK, Smiley ST. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun. 2006;74(6): 3381-3386.
82. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNFa-deficient mice: A critical requirement for TNFa in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184(4): 1397-1411.
83. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles. Drug Saf. 2001;24(12): 903-920.
84. Moon JJ, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater. 2011;10(3): 243-251.
85. Friede M, Muller S, Briand JP, Van Regenmortel MHV, Schuber F. Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A. Mol Immunol. 1993;30(6): 539-547.
86. de Titta A, et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013;110(49): 19902-19907.
87. Tewari K, et al. Poly(I: C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and aDEC-CSP in non human primates. Vaccine. 2010;28(45): 7256-7266.
88. Park H, et al. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol. 2013;190(8): 4103-4115.
89. Caskey M, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208(12): 2357-2366.
90. Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev. 2014;13(2): 299-312.
91. van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-Associated epitope gp100. Cancer Res. 2009;69(19): 7784-7792.
92. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129): 207-211.
93. Asselin-Paturel C, Brizard G, Pin J-J, Brière F, Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol. 2003;171(31): 6466-6477.
94. Fletcher AL, et al. Reproducible isolation of lymph node stromal cells reveals site-dependent differences in fibroblastic reticular cells. Front Immunol. 2011;2: 35.